Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Food Effect of ACT-451840 in Healthy Subjects
NCT02186002Phase 1Completed
- Sponsor
- Idorsia
- Start
- Dec 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-451840 in malaria (6 arms), sponsored by Idorsia. Primary endpoints: Change in systolic blood pressure from baseline at 4 days, Change in diastolic blood pressure from baseline at 4 days and 5 more. Started Dec 2011; status: completed.
02
Drugs
ACT-451840
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02186002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186002.